nanoparticle delivery
Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership
Exsilio Therapeutics, mRNA, genomic medicines, Tal Zaks, gene therapy, gene editing, lipid nanoparticle delivery, redosing, safety profile, gene therapy approval
Exsilio Emerges from Stealth with $82 Million to Revolutionize Gene Therapy
Exsilio Therapeutics, Gene Therapy, Novel Approach, mRNA, Lipid Nanoparticle Delivery, Biotech Company, Genetic Medicine